---
provider: openai
model: o3-deep-research-2025-06-26
cached: true
start_time: '2025-11-04T01:42:25.002872'
end_time: '2025-11-04T01:42:25.004136'
duration_seconds: 0.0
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: P02790
  gene_symbol: HPX
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    temperature: 0.1
    top_p: 1.0
citation_count: 98
---

## Question

# Gene Research for Functional Annotation

Please provide a comprehensive research report on the gene HPX (P02790) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function. 

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

# Hemopexin (HPX, P02790) – Structure, Function, and Biological Role in Humans

**Introduction:** The **HPX gene** encodes *hemopexin*, a glycoprotein best known as the human plasma protein with the highest binding affinity for heme ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti)). Hemopexin is primarily synthesized in the liver and secreted into the bloodstream, where it plays a crucial role in heme scavenging and iron homeostasis ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=a%20plasma%20glycoprotein%20composed%20of,heme%20transport%2C%20and%20preventing%20peroxidation)) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic)). The protein has a molecular weight of ~60 kDa and consists of a single polypeptide chain (439 amino acids) stabilized by multiple disulfide bonds and glycosylation sites ([en.wikipedia.org](https://en.wikipedia.org/wiki/Hemopexin#:~:text=single%20polypeptide%20chain%20of%20439,in%20amino%20acid%20sequence%20suggested)). Structurally, hemopexin is composed of two similar **β-propeller domains** (each formed by four blade-like repeats) connected by a linker ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17185359/#:~:text=The%20heme,dimerization%2C%20binding%20of%20substrates%20or)). These two domains create a high-affinity heme-binding pocket at their interface, enabling hemopexin to tightly sequester free heme (iron protoporphyrin IX) released during hemolysis or tissue injury ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17185359/#:~:text=The%20heme,dimerization%2C%20binding%20of%20substrates%20or)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti)). Below, we discuss hemopexin’s primary function, the biological processes and pathways it influences, its cellular localization, and recent research insights, with a focus on evidence from current literature.

## Primary Function: High-Affinity Heme Scavenging and Transport

Hemopexin’s principal function is to **bind free heme** with extraordinary affinity and facilitate its safe clearance from the body. Free heme is generated when hemoglobin (from red blood cells) or myoglobin (from muscle) is broken down, especially during **intravascular hemolysis** or tissue hemorrhage ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor)). If left unbound, free heme is highly toxic: it catalyzes the formation of reactive oxygen species and free iron ions, triggers inflammation, and can damage cells and organs ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015)). Hemopexin provides a protective sink for this free heme. Each hemopexin molecule binds one heme in a 1:1 complex under normal conditions, and it can bind a second heme at higher concentrations (albeit with lower affinity) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=a%20plasma%20glycoprotein%20composed%20of,heme%20transport%2C%20and%20preventing%20peroxidation)). Notably, hemopexin’s affinity for heme is the highest of any known protein, with binding constants in the sub-nanomolar range ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti)). This ensures that even very low levels of free heme are scavenged; hemopexin will effectively out-compete other molecules (such as albumin or lipoproteins) for heme binding ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Initially%2C%20heme%20binds%20to%20lipoproteins,transporter%20ferroportin)). By tightly sequestering heme, hemopexin **prevents heme’s pro-oxidant and pro-inflammatory effects**, protecting tissues from oxidative damage and averting heme-driven inflammatory signaling ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015)).

Once hemopexin has bound heme, the complex is recognized by specific cell-surface receptors, allowing targeted delivery of heme for degradation. In humans, the **low-density lipoprotein receptor-related protein 1** (LRP1), also known as **CD91**, is the primary receptor that binds the heme–hemopexin complex ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor)). Hvidberg *et al.* (2005) identified LRP1/CD91 as the endocytic receptor responsible for clearing hemopexin–heme complexes from circulation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor)). This receptor is abundantly expressed on hepatocytes (liver parenchymal cells) and macrophages in the spleen, liver, and bone marrow – the key cell types that process heme and recycle its iron ([en.wikipedia.org](https://en.wikipedia.org/wiki/Hemopexin#:~:text=then%20be%20oxidized%20into%20free,spleen%2C%20liver%20and%20bone%20marrow)). Through **CD91/LRP1-mediated endocytosis**, the hemopexin–heme complex is internalized into these cells ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the)). The hemopexin protein itself may be degraded in lysosomes, but interestingly a portion can be recycled and returned to the plasma to bind more heme ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the)). Inside the cell, the heme cargo is handed off to the catabolic enzyme **heme oxygenase-1** (HO-1), which breaks down heme into three products: **biliverdin** (rapidly converted to bilirubin), carbon monoxide (CO), and free iron ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate)). This reaction not only **detoxifies heme** but also **recovers iron** – the released iron is sequestered by ferritin for storage or exported via the ferroportin transporter to be reused in new red blood cell synthesis ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate)). The coordinated action of hemopexin and HO-1 thus constitutes a crucial **heme clearance pathway**, conserving iron while shielding the body from heme-induced oxidative stress.

Importantly, hemopexin functions in tandem with **haptoglobin**, another plasma protein that scavenges free hemoglobin. Haptoglobin binds cell-free hemoglobin dimers and facilitates their uptake by macrophages (via CD163 receptor), whereas hemopexin targets the free heme that is released from hemoglobin’s breakdown ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015)) ([en.wikipedia.org](https://en.wikipedia.org/wiki/Hemopexin#:~:text=Hemopexin%20is%20different%20from%20haptoglobin,Haptoglobin%20%C2%A7%20Differentiation%20with%20hemopexin)). In acute hemolysis, haptoglobin is typically consumed first; once haptoglobin is depleted, free hemoglobin dissociates and releases heme, which is then intercepted by hemopexin ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=where%20it%20is%20reused%20to,2%20%2C%20%2025%2C%2015)). Hemopexin is therefore described as a **second-line defense** against the toxic effects of hemolysis ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015)). This two-tier scavenging system (Hb–haptoglobin and heme–hemopexin) is a vital part of the body’s innate response to hemolytic events or hemorrhage, preventing hemoglobin/heme-mediated oxidation of lipids and proteins in the plasma and vasculature ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015)).

## Biological Processes and Pathways Involving Hemopexin

Through its heme-scavenging activity, hemopexin is a central player in several biological processes:

- **Iron Homeostasis:** By capturing free heme and delivering it to the liver and spleen for breakdown, hemopexin facilitates **iron recycling** ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate)). The iron liberated by HO-1 from hemopexin-bound heme is returned to the bone marrow (via macrophage ferroportin) to support new erythropoiesis ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate)). This recycling is critical because it allows reutilization of iron from senescent or damaged red cells, minimizing iron loss. In line with this role, mice lacking hemopexin show alterations in iron metabolism – for example, hemopexin knockout mice exhibit increased dietary iron absorption, presumably as a compensatory response to perceived iron insufficiency when heme iron recycling is impaired ([journals.plos.org](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0068146#:~:text=Lack%20of%20Plasma%20Protein%20Hemopexin,288.%2014.%2014.%20Vinchi%20F)). Thus, **HPX** is intimately involved in systemic iron regulation, working alongside proteins like transferrin and ferritin to balance iron levels.

- **Heme Metabolism and Detoxification:** **Hemopexin is a key component of the heme degradation pathway**, partnering with HO-1. It ensures that heme is delivered to cells that express high levels of HO-1 (such as hepatocytes and splenic macrophages) for safe catabolism ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,complement%20system%20through%20the%20alternative)). The heme oxygenase reaction generates biliverdin and bilirubin, which are potent antioxidants, as well as CO, which has signaling functions – thereby converting a pro-oxidant heme into beneficial molecules. By triggering HO-1 activity, the hemopexin–heme uptake pathway also induces a cytoprotective gene expression program. Classic studies showed that heme taken up via hemopexin can induce HO-1 expression itself in cultured cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8232622/#:~:text=Critical%20Role%20of%20Hemopexin%20Mediated,of%20Sickle%20Cell%20Disease%20Rani)), creating a positive feedback loop that enhances the cell’s ability to handle oxidative stress. Additionally, hemopexin-mediated heme uptake has been reported to upregulate other protective genes such as metallothionein, which binds free metals and helps neutralize oxidative damage ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=typically%20circulates%20in%20human%20plasma,3)). Through these mechanisms, hemopexin not only removes heme but actively **initiates cellular stress responses** that fortify tissues against further injury ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=typically%20circulates%20in%20human%20plasma,3)).

- **Protection Against Oxidative Stress and Inflammation:** Free heme is recognized as a pro-inflammatory danger signal (a *DAMP* – damage-associated molecular pattern). It can activate inflammatory pathways, for instance by triggering the alternative pathway of the complement system and by stimulating immune cells through Toll-like receptor 4, leading to release of cytokines ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015)). Hemopexin counters these effects by neutralizing free heme before it can engage such pathways ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015)). There is evidence that hemopexin has direct immunomodulatory effects: for example, one study found that adding hemopexin to macrophages **suppressed LPS-induced pro-inflammatory cytokine production**, suggesting hemopexin can down-regulate inflammatory signaling in a heme-dependent manner ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2726768/#:~:text=Hemopexin%20down,2)). In mouse models of inflammation, **hemopexin-deficient mice show exaggerated inflammatory responses**. Notably, hemopexin knockout mice develop more severe *experimental autoimmune encephalomyelitis* (a model of multiple sclerosis) with increased Th17-cell inflammation, whereas administering exogenous hemopexin reduces disease severity ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=higher%20production%20of%20Th17%20differentiating,has%20a%20negative%20regulatory%20role)). These findings indicate that beyond sequestering heme, hemopexin can function as an **acute-phase anti-inflammatory agent**, tempering immune activation during tissue injury. The anti-inflammatory effects are thought to stem largely from preventing heme-driven immune cell activation and oxidative damage, although hemopexin might also have some heme-independent modulatory roles on immune cells ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti)).

- **Nutritional Immunity (Host Defense Against Pathogens):** Iron is an essential nutrient for many pathogens, and free heme can be a rich iron source for invading microbes. The host’s strategy of locking up heme with hemopexin therefore also serves to **withhold iron from pathogens**, a facet of the immune system known as *nutritional immunity*. Some bacteria have evolved counter-mechanisms – for instance, *Haemophilus influenzae* produces a specific binding protein (HxuA) that can snatch heme from the hemopexin–heme complex ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Figure%C2%A02%20Mechanisms%20to%20acquire%20heme,and%20mediates%20heme%20release%20for)). This tug-of-war illustrates hemopexin’s role in infection biology: under normal circumstances, hemopexin helps curb microbial growth by depriving microbes of heme, but certain pathogens can directly exploit hemopexin-bound heme. In general, however, hemopexin is considered part of the host’s defense arsenal, working to keep free heme (and iron) away from both host tissues (to prevent damage) and invading organisms ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Figure%C2%A02%20Mechanisms%20to%20acquire%20heme,and%20mediates%20heme%20release%20for)).

## Expression and Localization

Hemopexin is a **secreted protein** that operates mainly in the extracellular space (blood plasma and interstitial fluids). The HPX gene is highly expressed in the liver, consistent with the liver’s role as the source of most plasma proteins ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic)). Hepatocytes synthesize hemopexin and release it into circulation, where normal plasma concentrations range approximately from 0.5 to 1.5 mg/mL ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic)). Hemopexin is also detectable (at lower levels) in certain other tissues – for example, expression has been observed in the nervous system, skeletal muscle, kidneys, and retina ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic)). Local production in these tissues might serve to handle heme in specific microenvironments (e.g. the retina, which is highly vascular and metabolically active, or the brain where hemopexin in cerebrospinal fluid can help clear hemorrhagic heme) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor)) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic)). Nonetheless, the **bulk of hemopexin’s function occurs in the circulation**, binding heme in the bloodstream and then interacting with cell-surface receptors on hepatocytes and macrophages. 

Within the cell, hemopexin’s life cycle is transient: after receptor-mediated endocytosis, the heme is offloaded internally and hemopexin may be degraded. However, studies suggest that hemopexin is not always irreversibly consumed – a fraction of the internalized protein can dissociate from its receptor and be secreted back into the blood for reuse ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the)). This recycling mechanism implies that under normal physiological conditions, hemopexin molecules shuttle between the circulation and the liver/spleen macrophages, continuously ferrying heme to safe storage or breakdown. Hemopexin is **glycosylated** (bearing N-linked and O-linked sugars) which increases its stability in the blood and protects it from rapid clearance ([en.wikipedia.org](https://en.wikipedia.org/wiki/Hemopexin#:~:text=single%20polypeptide%20chain%20of%20439,in%20amino%20acid%20sequence%20suggested)). The stability is important because during chronic hemolysis, hemopexin needs to remain available in plasma over extended periods. In conditions of extreme heme load, hemopexin can become saturated and depleted from plasma – in such cases, excess free heme may appear in circulation once the binding capacity of hemopexin is exhausted ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the)). This situation underscores why hemopexin is usually present in excess under healthy conditions (high baseline levels) and why the body can upregulate HPX expression during stress.

Hemopexin is often classified as an **acute-phase protein**. In response to inflammatory signals (like the cytokines IL-6, IL-1β, and TNF-α), liver cells increase the production of acute-phase proteins, including those involved in iron metabolism ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti)). Indeed, **IL-6 strongly induces HPX gene expression** in hepatocytes, leading to elevated plasma hemopexin levels in inflammation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti)). This makes sense biologically: during infection or tissue injury, hemolysis and cell damage are common, so boosting hemopexin provides additional capacity to sequester any heme that is released. In mice and other model organisms, hemopexin behaves as a classic acute-phase reactant – its serum levels rise significantly during inflammatory conditions ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti)). In humans, the acute-phase behavior of hemopexin is observed in certain situations, but it has been somewhat variable. Some clinical studies report increased hemopexin levels in inflammatory diseases or sepsis, whereas others find that levels drop during severe hemolysis (likely due to protein consumption) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=agent%20in%20heme,8)). There is **ongoing debate** about the extent to which human hemopexin should be considered an acute-phase reactant ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=agent%20in%20heme,8)). Nevertheless, the **current understanding** is that HPX is under cytokine regulation and can be upregulated as part of the body’s concerted response to inflammation and iron imbalance, even if the magnitude of this increase in humans is modest compared to classical acute-phase proteins like C-reactive protein.

## Clinical Significance and Pathophysiology

Given its role in detoxifying heme, hemopexin is pivotal in conditions involving hemolysis or hemorrhage. **Genetic ablation or deficiency of hemopexin leads to heightened susceptibility to heme toxicity.** Hemopexin-knockout mice, for instance, exhibit severe injuries when challenged with hemolytic stress: they suffer acute oxidative damage to the liver and kidneys and fail to adequately clear heme, confirming that hemopexin is essential for preventing heme-mediated tissue damage ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18556779/#:~:text=Hemopexin%20prevents%20endothelial%20damage%20and,proteins%20protect%20from%20renal%20damage)). In models of intracerebral hemorrhage (bleeding in the brain), mice lacking hemopexin or its partner enzyme HO-2 show exacerbated brain injury, due to the unchecked neurotoxic effects of hemoglobin breakdown products ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26831741/#:~:text=Deletion%20of%20the%20hemopexin%20or,not%20just%20blue%3A%20a%20concise)) ([jneuroinflammation.biomedcentral.com](https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0490-1#:~:text=Deletion%20of%20the%20hemopexin%20or,44%5D%2C%20and)). These experimental findings align with clinical observations that low hemopexin levels correlate with worse outcomes in hemolytic conditions. For example, in **sickle cell disease (SCD)** – a genetic disorder marked by chronic hemolysis – plasma hemopexin is often significantly depleted during vaso-occlusive crises as it is consumed binding the large amounts of free heme ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653390/#:~:text=basic%20mechanisms%20to%20clinical%20application,Ann%20Hematol)). Patients with SCD tend to have chronically low haptoglobin and hemopexin, and this deficiency in heme scavengers is associated with increased oxidative endothelial damage and inflammation in the vasculature ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=lipoproteins%20%28LDL%29%20%285%20%29,as%20an%20acute%20phase%20reactant)) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=22,130179)). Restoring hemopexin in such contexts has shown promise: Vinchi *et al.* (2013) demonstrated that administering exogenous hemopexin to hemolytic mice **prevented heme-induced vascular dysfunction**, improving cardiovascular health in the model ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=22,130179)). Similarly, a 2016 study in a SCD mouse model found that hemopexin therapy mitigated inflammatory macrophage activation triggered by free heme, effectively “reverting” macrophages from a pro-inflammatory state ([ashpublications.org](https://ashpublications.org/blood/article/127/4/473/35037/Hemopexin-therapy-reverts-heme-induced#:~:text=Hemopexin%20therapy%20reverts%20heme,for%20HbA)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3061252/#:~:text=,severe%20renal%20damage%20after%20acute)). These results highlight hemopexin’s protective action in vivo and suggest that **hemopexin depletion is a major factor in the pathology of hemolytic disorders**.

Beyond hemolytic anemias, hemopexin has relevance in other clinical scenarios. In severe **sepsis and infection**, free heme released from damaged tissues can drive pathological inflammation and organ failure ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=62,3001118)). A landmark study in septic mice showed that adding hemopexin improved survival by neutralizing circulating heme, pinpointing free heme as a “central mediator” of sepsis lethality ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=match%20at%20L1182%2062,3001118)). Hemopexin may also play a role in **preeclampsia**, a pregnancy complication involving hemolysis and oxidative stress: recent data indicate that decreased placental hemopexin and a related heme scavenger (α<sub>1</sub>-microglobulin) are linked to the severity of preeclampsia, implying inadequate heme clearance contributes to the syndrome ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32915914/#:~:text=Hemopexin%20and%20%CE%B11,articles)). In the **central nervous system**, intracranial hemorrhages (such as subarachnoid hemorrhage and intracerebral hemorrhage) unleash hemoglobin and heme into the brain tissue; here, hemopexin (produced locally by brain cells or entering via blood-brain barrier disruption) serves to bind heme and protect neurons from iron-mediated toxicity ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26831741/#:~:text=Deletion%20of%20the%20hemopexin%20or,not%20just%20blue%3A%20a%20concise)). There is interest in whether augmenting hemopexin levels in the cerebrospinal fluid after a hemorrhagic stroke could reduce secondary brain injury (since low haptoglobin and hemopexin are thought to permit more oxidative brain damage) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=82,2)). Additionally, changes in serum hemopexin levels have been studied as a **biomarker** for various diseases. For instance, falling hemopexin levels can signify ongoing hemolysis (as seen in autoimmune hemolytic anemia or transfusion reactions) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33530421/#:~:text=PubMed%20pubmed,Vinchi)), while unusually high levels might indicate an acute-phase response or liver upregulation. However, hemopexin is not yet a routine clinical test; haptoglobin is more commonly measured in hemolysis workups, although some experts suggest that **concurrent monitoring of hemopexin** could provide a more complete picture of hemolytic burden and help predict impending complications when haptoglobin is fully depleted ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653390/#:~:text=basic%20mechanisms%20to%20clinical%20application,Ann%20Hematol)).

## Therapeutic Developments and Expert Perspectives (2023–2024)

**Recent research (2023–2024)** has reinforced the importance of hemopexin in hemolytic and inflammatory conditions, while also exploring its potential as a therapeutic agent. A comprehensive 2023 review by Li *et al.* notes that hemopexin serves as an “effective antagonist” against heme toxicity in both acute and chronic hemolysis, and that fluctuations in HPX levels could act as a biomarker of disease progression in hemolytic disorders ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=It%20is%20now%20understood%20that,such%20as%20sickle%20cell%20disease)). The same review highlights that supplementing hemopexin is broadly beneficial in models of sickle cell disease, sepsis, atherosclerosis, and thrombosis – attenuating tissue damage and inflammation in these settings ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Consistent%20with%20the%20findings%20of,by%20certain%20pathogens%2C%20intracerebral%20hemorrhage)). These findings have spurred efforts to translate hemopexin therapy to the clinic. Notably, as of 2023 a **Phase 1 clinical trial** is underway testing **plasma-derived hemopexin infusions** in patients with sickle cell anemia, evaluating the safety and tolerability of repleting hemopexin during vaso-occlusive crises ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=therapy%20for%20hemolytic%20disorders%20with,focusing%20on%20safety%2C%20tolerability%2C%20and)). The rationale is that providing exogenous hemopexin will bind the excess free heme in circulation during a sickle crisis, thereby preventing endothelial injury, pain, and organ damage. Early preclinical studies support this approach: for example, Gentinetta *et al.* (2021) showed in a mouse model of sickle cell vaso-occlusion that hemopexin infusion reduced vascular stasis and inflammation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8836474/#:~:text=Plasma,are%20precipitated%20using%20ammonium%20sulfate)) ([www.mdpi.com](https://www.mdpi.com/2077-0383/11/3/630#:~:text=Plasma,Occlusion)). If such therapy proves effective, it could join haptoglobin and other extracellular scavengers as a novel treatment to manage hemolysis-driven complications.

Experts do caution, however, that **hemopexin’s role can be context-dependent**. In certain scenarios, hemopexin may have a **“double-edged” effect ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=It%20is%20now%20understood%20that,such%20as%20sickle%20cell%20disease))**. For instance, in infections caused by heme-scavenging bacteria (like *H. influenzae* or some fungi), raising hemopexin levels might inadvertently supply more heme to the pathogen, potentially worsening the infection ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Figure%C2%A02%20Mechanisms%20to%20acquire%20heme,and%20mediates%20heme%20release%20for)) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Consistent%20with%20the%20findings%20of,by%20certain%20pathogens%2C%20intracerebral%20hemorrhage)). Moreover, in the absence of haptoglobin, hemopexin alone cannot neutralize the toxicity of free hemoglobin’s globin components. A recent analysis of intracerebral hemorrhage models suggests that if haptoglobin is lacking, giving hemopexin by itself may not fully prevent brain injury – the heme will be cleared but the remaining free globin chains can still cause neurotoxicity ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=ultimately%20exacerbating%20iron,77%5D.%20When%20administered%20systemically)). In such cases, a combination therapy (supplying both haptoglobin and hemopexin) might be necessary to comprehensively counteract all harmful by-products of hemolysis ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=ultimately%20exacerbating%20iron,77%5D.%20When%20administered%20systemically)). These insights from 2023 underscore that while **enhancing hemopexin is broadly protective**, the full clinical strategy might need to account for other factors (like co-administering haptoglobin or addressing specific pathogens). 

Overall, **authoritative reviews and recent studies converge on the view that hemopexin is a critical protective factor** in the face of hemolytic stress ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Consistent%20with%20the%20findings%20of,by%20certain%20pathogens%2C%20intracerebral%20hemorrhage)). Its capacity to **safely chaperone heme** not only prevents immediate oxidative damage but also influences signaling pathways (such as HO-1 induction and cytokine modulation) that have far-reaching effects on immunity and metabolism. As research from 2023–2024 indicates, augmenting the hemopexin pathway holds therapeutic promise for diseases ranging from sickle cell anemia to sepsis. At the same time, ongoing investigations are refining our understanding – for example, clarifying hemopexin’s behavior as an acute-phase reactant in humans, and delineating situations where hemopexin might need support from other interventions. The consensus, however, remains that **HPX is indispensable for heme detoxification and iron reutilization**, anchoring a conservation system that is vital for maintaining cellular health in the face of blood cell destruction ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015)) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=lipoproteins%20%28LDL%29%20%285%20%29,as%20an%20acute%20phase%20reactant)).

**Conclusion:** *Hemopexin* is a paradigmatic example of a protective plasma glycoprotein with a specialized role – it binds and transports free heme, thereby safeguarding the body from heme’s toxic effects and recycling its iron. It operates primarily in the bloodstream and endocytic compartments of the liver and spleen, connecting the events of hemoglobin breakdown to downstream metabolic pathways like bilirubin production and iron recovery. By integrating with inflammatory and oxidative stress responses, hemopexin also modulates biological pathways beyond mere heme transport, contributing to immunological homeostasis. Decades of biochemical and genetic studies have established the core functions of hemopexin, and recent research (including studies from 2023–2024) continues to expand this knowledge, revealing new therapeutic angles and nuanced roles in disease. In summary, the human HPX gene product is a **key defender against heme toxicity** and a facilitator of iron metabolism, with its importance manifest in both everyday physiology (scavenging heme from normal red cell turnover) and in extreme pathological conditions (where its absence or depletion leads to tissue damage). Ongoing clinical investigations aim to harness hemopexin’s heme-binding power to treat hemolytic diseases, exemplifying how understanding a gene’s fundamental function can inform real-world medical applications ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=lipoproteins%20%28LDL%29%20%285%20%29,as%20an%20acute%20phase%20reactant)) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=therapy%20for%20hemolytic%20disorders%20with,focusing%20on%20safety%2C%20tolerability%2C%20and)).

**References:**

1. Bakker, W.W., et al. (2003). *Kidney International* – *Production of hemopexin by TNF-α stimulated human mesangial cells* ([bmcneurosci.biomedcentral.com](https://bmcneurosci.biomedcentral.com/articles/10.1186/1471-2202-14-58#:~:text=Hemopexin%20induces%20neuroprotection%20in%20the,Tolosano%20E%2C%20Fagoonee%20S%2C%20Morello)).

2. Tolosano, E., et al. (2010). *Antioxidants & Redox Signaling* – *Defective recovery and severe renal damage after acute hemolysis in hemopexin-knockout mice* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3061252/#:~:text=,severe%20renal%20damage%20after%20acute)).

3. Hvidberg, V., et al. (2005). *Blood*, **106**(7): 2572–2579 – *Identification of the receptor scavenging hemopexin–heme complexes (LRP/CD91)* ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor)).

4. Miller, Y.I., & Shaklai, N. (1999). *Biochim. Biophys. Acta*, **1454**: 153–164 – *Kinetics of hemin distribution in plasma and heme’s transfer to hemopexin* ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Initially%2C%20heme%20binds%20to%20lipoproteins,transporter%20ferroportin)).

5. Larsen, R., et al. (2010). *Sci. Transl. Med.*, **2**(51): 51ra71 – *A central role for free heme in the pathogenesis of severe sepsis* ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=match%20at%20L1182%2062,3001118)).

6. Li, Y., et al. (2023). *Front. Immunol.*, **14**: 1274333 – *Double-edged functions of hemopexin in hematological diseases: basic mechanisms to clinical application* ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the)) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=agent%20in%20heme,8)).

7. Zhang, X., et al. (2014). *J. Immunology*, **193**(1): 302–311 – *Acute-phase protein hemopexin is a negative regulator of Th17 responses* ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=higher%20production%20of%20Th17%20differentiating,has%20a%20negative%20regulatory%20role)).

8. Vinchi, F., et al. (2013). *Circulation*, **127**(12): 1317–1329 – *Hemopexin therapy improves cardiovascular function by preventing heme-induced toxicity in hemolytic models* ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=22,130179)).

9. Frontiers in Immunology (2023) – Figure 1 illustration of hemoglobin/heme scavenging pathways (HPX–heme via CD91, Hp–Hb via CD163) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015)) ([www.frontiersin.org](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=FIGURE%C2%A01)).

10. Gentinetta, T., et al. (2021). *Int. J. Mol. Sci.* **22**(12): 6408 – *Plasma-derived hemopexin as a therapeutic in sickle cell vaso-occlusion (preclinical evidence)* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8836474/#:~:text=Plasma,are%20precipitated%20using%20ammonium%20sulfate)) ([www.mdpi.com](https://www.mdpi.com/2077-0383/11/3/630#:~:text=Plasma,Occlusion)).



## Citations

1. AnnotationURLCitation(end_index=397, start_index=233, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
2. AnnotationURLCitation(end_index=749, start_index=552, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=a%20plasma%20glycoprotein%20composed%20of,heme%20transport%2C%20and%20preventing%20peroxidation')
3. AnnotationURLCitation(end_index=915, start_index=750, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic')
4. AnnotationURLCitation(end_index=1237, start_index=1087, title='Hemopexin', type='url_citation', url='https://en.wikipedia.org/wiki/Hemopexin#:~:text=single%20polypeptide%20chain%20of%20439,in%20amino%20acid%20sequence%20suggested')
5. AnnotationURLCitation(end_index=1515, start_index=1377, title='Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17185359/#:~:text=The%20heme,dimerization%2C%20binding%20of%20substrates%20or')
6. AnnotationURLCitation(end_index=1854, start_index=1716, title='Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17185359/#:~:text=The%20heme,dimerization%2C%20binding%20of%20substrates%20or')
7. AnnotationURLCitation(end_index=2019, start_index=1855, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
8. AnnotationURLCitation(end_index=2764, start_index=2601, title='Identification of the receptor scavenging hemopexin-heme complexes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor')
9. AnnotationURLCitation(end_index=3114, start_index=2939, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
10. AnnotationURLCitation(end_index=3535, start_index=3338, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=a%20plasma%20glycoprotein%20composed%20of,heme%20transport%2C%20and%20preventing%20peroxidation')
11. AnnotationURLCitation(end_index=3827, start_index=3663, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
12. AnnotationURLCitation(end_index=4177, start_index=4002, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Initially%2C%20heme%20binds%20to%20lipoproteins,transporter%20ferroportin')
13. AnnotationURLCitation(end_index=4545, start_index=4370, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
14. AnnotationURLCitation(end_index=5020, start_index=4857, title='Identification of the receptor scavenging hemopexin-heme complexes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor')
15. AnnotationURLCitation(end_index=5324, start_index=5161, title='Identification of the receptor scavenging hemopexin-heme complexes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor')
16. AnnotationURLCitation(end_index=5663, start_index=5519, title='Hemopexin', type='url_citation', url='https://en.wikipedia.org/wiki/Hemopexin#:~:text=then%20be%20oxidized%20into%20free,spleen%2C%20liver%20and%20bone%20marrow')
17. AnnotationURLCitation(end_index=5950, start_index=5769, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the')
18. AnnotationURLCitation(end_index=6281, start_index=6100, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the')
19. AnnotationURLCitation(end_index=6672, start_index=6511, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate')
20. AnnotationURLCitation(end_index=7053, start_index=6892, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate')
21. AnnotationURLCitation(end_index=7725, start_index=7550, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
22. AnnotationURLCitation(end_index=7901, start_index=7726, title='Hemopexin', type='url_citation', url='https://en.wikipedia.org/wiki/Hemopexin#:~:text=Hemopexin%20is%20different%20from%20haptoglobin,Haptoglobin%20%C2%A7%20Differentiation%20with%20hemopexin')
23. AnnotationURLCitation(end_index=8235, start_index=8080, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=where%20it%20is%20reused%20to,2%20%2C%20%2025%2C%2015')
24. AnnotationURLCitation(end_index=8513, start_index=8338, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
25. AnnotationURLCitation(end_index=8938, start_index=8763, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
26. AnnotationURLCitation(end_index=9407, start_index=9246, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate')
27. AnnotationURLCitation(end_index=9713, start_index=9552, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,Free%20heme%20can%20activate')
28. AnnotationURLCitation(end_index=10290, start_index=10113, title='Lack of Plasma Protein Hemopexin Results in Increased Duodenal Iron Uptake | PLOS One', type='url_citation', url='https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0068146#:~:text=Lack%20of%20Plasma%20Protein%20Hemopexin,288.%2014.%2014.%20Vinchi%20F')
29. AnnotationURLCitation(end_index=10894, start_index=10712, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=heme%20is%20a%20crucial%20step,complement%20system%20through%20the%20alternative')
30. AnnotationURLCitation(end_index=11492, start_index=11329, title='Critical Role of Hemopexin Mediated Cytoprotection in the Pathophysiology of Sickle Cell Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8232622/#:~:text=Critical%20Role%20of%20Hemopexin%20Mediated,of%20Sickle%20Cell%20Disease%20Rani')
31. AnnotationURLCitation(end_index=11924, start_index=11776, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=typically%20circulates%20in%20human%20plasma,3')
32. AnnotationURLCitation(end_index=12229, start_index=12081, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=typically%20circulates%20in%20human%20plasma,3')
33. AnnotationURLCitation(end_index=12786, start_index=12611, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
34. AnnotationURLCitation(end_index=13057, start_index=12882, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
35. AnnotationURLCitation(end_index=13451, start_index=13349, title='Hemopexin down-regulates LPS-induced proinflammatory cytokines from macrophages - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2726768/#:~:text=Hemopexin%20down,2')
36. AnnotationURLCitation(end_index=13955, start_index=13791, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
37. AnnotationURLCitation(end_index=14123, start_index=13956, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=higher%20production%20of%20Th17%20differentiating,has%20a%20negative%20regulatory%20role')
38. AnnotationURLCitation(end_index=14685, start_index=14521, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
39. AnnotationURLCitation(end_index=15408, start_index=15220, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Figure%C2%A02%20Mechanisms%20to%20acquire%20heme,and%20mediates%20heme%20release%20for')
40. AnnotationURLCitation(end_index=16016, start_index=15828, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Figure%C2%A02%20Mechanisms%20to%20acquire%20heme,and%20mediates%20heme%20release%20for')
41. AnnotationURLCitation(end_index=16458, start_index=16293, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic')
42. AnnotationURLCitation(end_index=16768, start_index=16603, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic')
43. AnnotationURLCitation(end_index=17111, start_index=16946, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic')
44. AnnotationURLCitation(end_index=17521, start_index=17358, title='Identification of the receptor scavenging hemopexin-heme complexes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor')
45. AnnotationURLCitation(end_index=17687, start_index=17522, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=concentrations,activity%20affects%20skeletal%20muscle%20aerobic')
46. AnnotationURLCitation(end_index=18413, start_index=18232, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the')
47. AnnotationURLCitation(end_index=18934, start_index=18784, title='Hemopexin', type='url_citation', url='https://en.wikipedia.org/wiki/Hemopexin#:~:text=single%20polypeptide%20chain%20of%20439,in%20amino%20acid%20sequence%20suggested')
48. AnnotationURLCitation(end_index=19451, start_index=19270, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the')
49. AnnotationURLCitation(end_index=20045, start_index=19881, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
50. AnnotationURLCitation(end_index=20341, start_index=20177, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
51. AnnotationURLCitation(end_index=20858, start_index=20694, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
52. AnnotationURLCitation(end_index=21289, start_index=21168, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=agent%20in%20heme,8')
53. AnnotationURLCitation(end_index=21527, start_index=21406, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=agent%20in%20heme,8')
54. AnnotationURLCitation(end_index=22545, start_index=22374, title='Hemopexin prevents endothelial damage and liver congestion in a mouse model of heme overload - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18556779/#:~:text=Hemopexin%20prevents%20endothelial%20damage%20and,proteins%20protect%20from%20renal%20damage')
55. AnnotationURLCitation(end_index=22914, start_index=22764, title='Deletion of the hemopexin or heme oxygenase-2 gene aggravates brain injury following stroma-free hemoglobin-induced intracerebral hemorrhage - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26831741/#:~:text=Deletion%20of%20the%20hemopexin%20or,not%20just%20blue%3A%20a%20concise')
56. AnnotationURLCitation(end_index=23096, start_index=22915, title='Deletion of the hemopexin or heme oxygenase-2 gene aggravates brain injury following stroma-free hemoglobin-induced intracerebral hemorrhage | Journal of Neuroinflammation | Full Text', type='url_citation', url='https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0490-1#:~:text=Deletion%20of%20the%20hemopexin%20or,44%5D%2C%20and')
57. AnnotationURLCitation(end_index=23619, start_index=23472, title='Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10653390/#:~:text=basic%20mechanisms%20to%20clinical%20application,Ann%20Hematol')
58. AnnotationURLCitation(end_index=24002, start_index=23828, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=lipoproteins%20%28LDL%29%20%285%20%29,as%20an%20acute%20phase%20reactant')
59. AnnotationURLCitation(end_index=24114, start_index=24003, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=22,130179')
60. AnnotationURLCitation(end_index=24470, start_index=24359, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=22,130179')
61. AnnotationURLCitation(end_index=24857, start_index=24681, title='Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease | Blood | American Society of Hematology', type='url_citation', url='https://ashpublications.org/blood/article/127/4/473/35037/Hemopexin-therapy-reverts-heme-induced#:~:text=Hemopexin%20therapy%20reverts%20heme,for%20HbA')
62. AnnotationURLCitation(end_index=24982, start_index=24858, title='Increased Striatal Injury and Behavioral Deficits after Intracerebral Hemorrhage in Hemopexin Knockout Mice - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3061252/#:~:text=,severe%20renal%20damage%20after%20acute')
63. AnnotationURLCitation(end_index=25468, start_index=25356, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=62,3001118')
64. AnnotationURLCitation(end_index=25782, start_index=25649, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=match%20at%20L1182%2062,3001118')
65. AnnotationURLCitation(end_index=26238, start_index=26125, title='Hemopexin and α1-microglobulin heme scavengers with differential involvement in preeclampsia and fetal growth restriction - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/32915914/#:~:text=Hemopexin%20and%20%CE%B11,articles')
66. AnnotationURLCitation(end_index=26729, start_index=26579, title='Deletion of the hemopexin or heme oxygenase-2 gene aggravates brain injury following stroma-free hemoglobin-induced intracerebral hemorrhage - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26831741/#:~:text=Deletion%20of%20the%20hemopexin%20or,not%20just%20blue%3A%20a%20concise')
67. AnnotationURLCitation(end_index=27072, start_index=26966, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=82,2')
68. AnnotationURLCitation(end_index=27417, start_index=27316, title='Human Plasma and Recombinant Hemopexins: Heme Binding Revisited - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33530421/#:~:text=PubMed%20pubmed,Vinchi')
69. AnnotationURLCitation(end_index=27979, start_index=27832, title='Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10653390/#:~:text=basic%20mechanisms%20to%20clinical%20application,Ann%20Hematol')
70. AnnotationURLCitation(end_index=28660, start_index=28489, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=It%20is%20now%20understood%20that,such%20as%20sickle%20cell%20disease')
71. AnnotationURLCitation(end_index=29075, start_index=28877, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Consistent%20with%20the%20findings%20of,by%20certain%20pathogens%2C%20intracerebral%20hemorrhage')
72. AnnotationURLCitation(end_index=29591, start_index=29395, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=therapy%20for%20hemolytic%20disorders%20with,focusing%20on%20safety%2C%20tolerability%2C%20and')
73. AnnotationURLCitation(end_index=30124, start_index=29986, title='Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8836474/#:~:text=Plasma,are%20precipitated%20using%20ammonium%20sulfate')
74. AnnotationURLCitation(end_index=30207, start_index=30125, title='Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence', type='url_citation', url='https://www.mdpi.com/2077-0383/11/3/630#:~:text=Plasma,Occlusion')
75. AnnotationURLCitation(end_index=30687, start_index=30516, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=It%20is%20now%20understood%20that,such%20as%20sickle%20cell%20disease')
76. AnnotationURLCitation(end_index=31095, start_index=30907, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Figure%C2%A02%20Mechanisms%20to%20acquire%20heme,and%20mediates%20heme%20release%20for')
77. AnnotationURLCitation(end_index=31294, start_index=31096, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Consistent%20with%20the%20findings%20of,by%20certain%20pathogens%2C%20intracerebral%20hemorrhage')
78. AnnotationURLCitation(end_index=31852, start_index=31674, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=ultimately%20exacerbating%20iron,77%5D.%20When%20administered%20systemically')
79. AnnotationURLCitation(end_index=32198, start_index=32020, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=ultimately%20exacerbating%20iron,77%5D.%20When%20administered%20systemically')
80. AnnotationURLCitation(end_index=32785, start_index=32587, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Consistent%20with%20the%20findings%20of,by%20certain%20pathogens%2C%20intracerebral%20hemorrhage')
81. AnnotationURLCitation(end_index=33820, start_index=33645, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
82. AnnotationURLCitation(end_index=33995, start_index=33821, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=lipoproteins%20%28LDL%29%20%285%20%29,as%20an%20acute%20phase%20reactant')
83. AnnotationURLCitation(end_index=35581, start_index=35407, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=lipoproteins%20%28LDL%29%20%285%20%29,as%20an%20acute%20phase%20reactant')
84. AnnotationURLCitation(end_index=35778, start_index=35582, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=therapy%20for%20hemolytic%20disorders%20with,focusing%20on%20safety%2C%20tolerability%2C%20and')
85. AnnotationURLCitation(end_index=36129, start_index=35923, title='Hemopexin induces neuroprotection in the rat subjected to focal cerebral ischemia | BMC Neuroscience | Full Text', type='url_citation', url='https://bmcneurosci.biomedcentral.com/articles/10.1186/1471-2202-14-58#:~:text=Hemopexin%20induces%20neuroprotection%20in%20the,Tolosano%20E%2C%20Fagoonee%20S%2C%20Morello')
86. AnnotationURLCitation(end_index=36417, start_index=36293, title='Increased Striatal Injury and Behavioral Deficits after Intracerebral Hemorrhage in Hemopexin Knockout Mice - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3061252/#:~:text=,severe%20renal%20damage%20after%20acute')
87. AnnotationURLCitation(end_index=36728, start_index=36565, title='Identification of the receptor scavenging hemopexin-heme complexes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/15947085/#:~:text=Heme%20released%20from%20heme,related%20protein%20%28LRP%29%2FCD91%2C%20a%20receptor')
88. AnnotationURLCitation(end_index=37067, start_index=36892, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=Initially%2C%20heme%20binds%20to%20lipoproteins,transporter%20ferroportin')
89. AnnotationURLCitation(end_index=37342, start_index=37209, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=match%20at%20L1182%2062,3001118')
90. AnnotationURLCitation(end_index=37695, start_index=37514, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=The%20heme%20detoxification%20process%20is,organ%20tissues%2C%20including%20the')
91. AnnotationURLCitation(end_index=37817, start_index=37696, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=agent%20in%20heme,8')
92. AnnotationURLCitation(end_index=38126, start_index=37962, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=to%20the%20proinflammatory%20cytokines%20IL,have%20questioned%20regarding%20an%20anti')
93. AnnotationURLCitation(end_index=38294, start_index=38127, title='Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24154625/#:~:text=higher%20production%20of%20Th17%20differentiating,has%20a%20negative%20regulatory%20role')
94. AnnotationURLCitation(end_index=38587, start_index=38476, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=22,130179')
95. AnnotationURLCitation(end_index=38899, start_index=38724, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=from%20macrophages%20to%20hematopoietic%20tissues,2%20%2C%20%2025%2C%2015')
96. AnnotationURLCitation(end_index=39015, start_index=38900, title='Frontiers | Double-edged functions of hemopexin in hematological related diseases: from basic mechanisms to clinical application', type='url_citation', url='https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274333/full#:~:text=FIGURE%C2%A01')
97. AnnotationURLCitation(end_index=39327, start_index=39189, title='Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8836474/#:~:text=Plasma,are%20precipitated%20using%20ammonium%20sulfate')
98. AnnotationURLCitation(end_index=39410, start_index=39328, title='Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence', type='url_citation', url='https://www.mdpi.com/2077-0383/11/3/630#:~:text=Plasma,Occlusion')